13 July 2022 - Newly published final guidance by NICE in the UK confirms its prior draft recommendation for the use of Vazkepa (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]), controlled LDL-C between 1.04 mmol/L - 2.60 mmol/L and established cardiovascular disease.
Amarin Corporation today announced that NICE has issued its final guidance recommending Vazkepa (icosapent ethyl) for reimbursement and use across the NHS in England and Wales to help reduce the risk of major cardiovascular disease events in high-risk statin-treated patients with established cardiovascular disease, at a price of £144.21 per 120 soft capsules (i.e. 30 day supply; the equivalent of approximately 171 EUR or 172 USD.